Treatment of humoral rejection with rituximab.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12400781.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Humoral vascular rejection is a B cell-mediated production of immunoglobulin G antibody against the transplanted organ. Available treatments of vascular rejection offer limited success, and chronic manifestations of vascular rejection require retransplantation. On the basis of the mechanism of action of rituximab, we successfully treated 1 patient with vascular rejection refractory to plasmapheresis with this drug without major toxicity.
Medical subject headings
- Antibodies, Monoclonal
- B-Lymphocytes
- Graft Rejection
- Heart Transplantation